|
1
|
Eckardt KU, Coresh J, Devuyst O, Johnson
RJ, Köttgen A, Levey AS and Levin A: Evolving importance of kidney
disease: From subspecialty to global health burden. Lancet.
382:158–169. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sharif MU, Elsayed ME and Stack AG: The
global nephrology workforce: Emerging threats and potential
solutions. Clin Kidney J. 9:11–22. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Couser WG, Remuzzi G, Mendis S and Tonelli
M: The contribution of chronic kidney disease to the global burden
of major noncommunicable diseases. Kidney Int. 80:1258–1270. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
No authors listed. The global issue of
kidney disease. Lancet. 382:1012013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Braun L, Sood V, Hogue S, Lieberman B and
Copley-Merriman C: High burden and unmet patient needs in chronic
kidney disease. Int J Nephrol Renovasc Dis. 5:151–163. 2012.
|
|
6
|
Liu Y: Cellular and molecular mechanisms
of renal fibrosis. Nat Rev Nephrol. 7:684–696. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
He W and Dai C: Key Fibrogenic Signaling.
Curr Pathobiol Rep. 3:183–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xia J, He LQ and Su X: Interventional
mechanisms of herbs or herbal extracts on renal interstitial
fibrosis. J Integr Med. 14:165–173. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morikawa M, Derynck R and Miyazono K:
TGF-β and the TGF-β family: Context-dependent roles in cell and
tissue physiology. Cold Spring Harb Perspect Biol. 8:a0218732016.
View Article : Google Scholar
|
|
10
|
Kim D, Lee AS, Jung YJ, Yang KH, Lee S,
Park SK, Kim W and Kang KP: Tamoxifen ameliorates renal
tubulointerstitial fibrosis by modulation of estrogen receptor
α-mediated transforming growth factor-β1/Smad signaling pathway.
Nephrol Dial Transplant. 29:2043–2053. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chateauvieux S, Morceau F, Dicato M and
Diederich M: Molecular and therapeutic potential and toxicity of
valproic acid. J Biomed Biotechnol. 479364:2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Blaheta RA, Michaelis M, Driever PH and
Cinatl J Jr: Evolving anticancer drug valproic acid: Insights into
the mechanism and clinical studies. Med Res Rev. 25:383–397. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Göttlicher M, Minucci S, Zhu P, Krämer OH,
Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG,
et al: Valproic acid defines a novel class of HDAC inhibitors
inducing differentiation of transformed cells. EMBO J.
20:6969–6978. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu N and Zhuang S: Treatment of chronic
kidney diseases with histone deacetylase inhibitors. Front Physiol.
6:1212015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Khan S, Jena G and Tikoo K: Sodium
valproate ameliorates diabetes-induced fibrosis and renal damage by
the inhibition of histone deacetylases in diabetic rat. Exp Mol
Pathol. 98:230–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Van Beneden K, Geers C, Pauwels M,
Mannaerts I, Verbeelen D, van Grunsven LA and Van den Branden C:
Valproic acid attenuates proteinuria and kidney injury. J Am Soc
Nephrol. 22:1863–1875. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng Q, Liu W, Liu Z, Zhao H, Han X and
Zhao M: Valproic acid protects septic mice from renal injury by
reducing the inflammatory response. J Surg Res. 192:163–169. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chevalier RL, Forbes MS and Thornhill BA:
Ureteral obstruction as a model of renal interstitial fibrosis and
obstructive nephropathy. Kidney Int. 75:1145–1152. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Meng XM, Nikolic-Paterson DJ and Lan HY:
Inflammatory processes in renal fibrosis. Nat Rev Nephrol.
10:493–503. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kovacs EJ and DiPietro LA: Fibrogenic
cytokines and connective tissue production. FASEB J. 8:854–861.
1994.PubMed/NCBI
|
|
21
|
Meng XM, Nikolic-Paterson DJ and Lan HY:
TGF-β: The master regulator of fibrosis. Nat Rev Nephrol.
12:325–338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lupher ML Jr and Gallatin WM: Regulation
of fibrosis by the immune system. Adv Immunol. 89:245–288. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wynn TA and Ramalingam TR: Mechanisms of
fibrosis: Therapeutic translation for fibrotic disease. Nat Med.
18:1028–1040. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Grande MT and López-Novoa JM: Fibroblast
activation and myofibroblast generation in obstructive nephropathy.
Nat Rev Nephrol. 5:319–328. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alikhan MA and Ricardo SD: Mononuclear
phagocyte system in kidney disease and repair. Nephrology
(Carlton). 18:81–91. 2013. View Article : Google Scholar
|
|
26
|
Boor P, Ostendorf T and Floege J: Renal
fibrosis: Novel insights into mechanisms and therapeutic targets.
Nat Rev Nephrol. 6:643–656. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Genovese F, Manresa AA, Leeming DJ,
Karsdal MA and Boor P: The extracellular matrix in the kidney: A
source of novel non-invasive biomarkers of kidney fibrosis.
Fibrogenesis Tissue Repair. 7:42014. View Article : Google Scholar
|
|
28
|
Seet LF, Toh LZ, Finger SN, Chu SW,
Stefanovic B and Wong TT: Valproic acid suppresses collagen by
selective regulation of Smads in conjunctival fibrosis. J Mol Med
(Berl). 94:321–334. 2016. View Article : Google Scholar
|
|
29
|
Arpino V, Brock M and Gill SE: The role of
TIMPs in regulation of extracellular matrix proteolysis. Matrix
Biol. 44–46. 247–254. 2015.
|
|
30
|
Dupuis RE, Lichtman SN and Pollack GM:
Acute valproic acid overdose. Clinical course and pharmacokinetic
disposition of valproic acid and metabolites. Drug Saf. 5:65–71.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dealberto MJ: Valproate-induced
hyperammonaemic encephalopathy: Review of 14 cases in the
psychiatric setting. Int Clin Psychopharmacol. 22:330–337. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bryant AE III and Dreifuss FE: Valproic
acid hepatic fatalities. III. U.S. experience since 1986.
Neurology. 46:465–469. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zaki EL and Springate JE: Renal injury
from valproic acid: Case report and literature review. Pediatr
Neurol. 27:318–319. 2002. View Article : Google Scholar : PubMed/NCBI
|
